Authors: SANNER MA CHAPPIE TA DUNAISKIS AR FLIRI AF DESAI KA ZORN SH JACKSON ER JOHNSON CG MORRONE JM SEYMOUR PA MAJCHRZAK MJ FARACI WS COLLINS JL DUIGNAN DB DIPRETE CC LEE JS TROZZI A

Citation: Ma. Sanner et al., SYNTHESIS, SAR AND PHARMACOLOGY OF CP-293,019 - A POTENT, SELECTIVE DOPAMINE D-4 RECEPTOR ANTAGONIST, Bioorganic & medicinal chemistry letters, 8(7), 1998, pp. 725-730

Authors: MCLEAN S GANONG A SEYMOUR PA BRYCE DK CRAWFORD RT MORRONE J REYNOLDS LS SCHMIDT AW ZORN S WATSON J FOSSA A DEPASQUALE M ROSEN T NAGAHISA A TSUCHIYA M HEYM J

Citation: S. Mclean et al., CHARACTERIZATION OF CP-122,721 - A NONPEPTIDE ANTAGONIST OF THE NEUROKININ NK1 RECEPTOR, The Journal of pharmacology and experimental therapeutics, 277(2), 1996, pp. 900-908

Authors: HOWARD HR LOWE JA SEEGER TF SEYMOUR PA ZORN SH MALONEY PR EWING FE NEWMAN ME SCHMIDT AW FURMAN JS ROBINSON GL JACKSON E JOHNSON C MORRONE J

Citation: Hr. Howard et al., 3-BENZISOTHIAZOLYLPIPERAZINE DERIVATIVES AS POTENTIAL ATYPICAL ANTIPSYCHOTIC AGENTS, Journal of medicinal chemistry, 39(1), 1996, pp. 143-148

Authors: MACOR JE BLANK DH DESAI K FOX CB KOE BK LEBEL LA POST RJ SCHMIDT AW SCHULZ DW SEYMOUR PA

Citation: Je. Macor et al., O-1-[3-(N-METHYLPYRROLIDIN-2R-YLMETHYL)INDOL-5-YL] BENZIMIDAZOLE (CP-161,242) - A POTENT, CENTRALLY ACTIVE 5-HT1D RECEPTOR AGONIST AND BENZODIAZEPINE PARTIAL AGONIST, Bioorganic & medicinal chemistry letters, 5(20), 1995, pp. 2391-2396

Authors: SEEGER TF SEYMOUR PA SCHMIDT AW ZORN SH SCHULZ DW LEBEL LA MCLEAN S GUANOWSKY V HOWARD HR LOWE JA HEYM J

Citation: Tf. Seeger et al., ZIPRASIDONE (CP-88,059) - A NEW ANTIPSYCHOTIC WITH COMBINED DOPAMINE AND SEROTONIN RECEPTOR ANTAGONIST ACTIVITY, The Journal of pharmacology and experimental therapeutics, 275(1), 1995, pp. 101-113

Authors: MCLEAN S GANONG A SEYMOUR PA SNIDER RM DESAI MC ROSEN T BRYCE DK LONGO KP REYNOLDS LS ROBINSON G SCHMIDT AW SIOK C HEYM J

Citation: S. Mclean et al., PHARMACOLOGY OF CP-99,994 - A NONPEPTIDE ANTAGONIST OF THE TACHYKININNEUROKININ-1 RECEPTOR, The Journal of pharmacology and experimental therapeutics, 267(1), 1993, pp. 472-479